Compare Bristol-Myers Squibb Co (BMY) vs EOG Resources Inc (EOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs EOG Resources Inc — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $116.30B), while EOG Resources Inc trades at $138.97 (market cap $73.51B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | EOG | |
|---|---|---|
Market Cap | $116.30B | $73.51B |
Sector | Health | Energy |
52-Week High | $62.37 | $149.89 |
52-Week Low | $42.60 | $101.78 |
Enterprise Value | $152.24B | $77.97B |
Dividend Yield | 4.42% | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
EOG Resources trades at $139.61, up 4.11% with a bullish technical outlook. The stock shows strong profitability with a net margin of 23.39% and ROE of 18.19%, supported by consistent earnings beats. Valuation ratios like P/E of 13.73 and EV/EBITDA of 6.6 appear attractive relative to historical levels. Recent news highlights operational excellence and dividend stability, with Q2 2026 earnings anticipated on August 5, 2026.
The outlook remains positive with a consensus price target of $156.40, implying 12% upside. Risks include oil price volatility and elevated capital expenditures, but EOG's low-cost production and solid balance sheet provide resilience. Analyst sentiment is strongly bullish with no sell ratings, reinforcing the investment case for growth and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
